Why GW Pharmaceuticals (GWPH) Stock Is Soaring Today

NEW YORK (TheStreet) -- GW Pharmaceuticals (GWPH) stock is soaring, up 31.1% to $60.37 in trading on Tuesday.

The increase follows coverage initiation on the cannabis prescription drug company's stock with an "overweight" rating by analysts at Morgan Stanley (MS). The firm set a $103 price target on the company's shares.

Must Read: Warren Buffett's 10 Favorite Stocks

SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more.

Analysts see the company's cannabis based epilepsy treatment drug, Epidiolex, as having "strong potential, with the epilepsy program driving valuation."

"While small and still anecdotal, there is a consistently strong and building set of data (case cohort and controlled) which highlight the positive impact of Cannabidiol  on refractory epilepsy pts," the firm said.

GWPH Chart

GWPH data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.


More from Markets

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

Dow Rises for First Time in 9 Days, Oil Soars as OPEC Agrees to Boost Output

Dow Rises for First Time in 9 Days, Oil Soars as OPEC Agrees to Boost Output

Jim Cramer: Some Industrials Stocks Are Becoming Great Values

Jim Cramer: Some Industrials Stocks Are Becoming Great Values

Jim Cramer Reacts to Toni Sacconaghi's Latest Tesla Note

Jim Cramer Reacts to Toni Sacconaghi's Latest Tesla Note

Howard Schultz to Jim Cramer: Starbucks Stock Is Cheap and Undervalued

Howard Schultz to Jim Cramer: Starbucks Stock Is Cheap and Undervalued